Haskologlu,  Ismail Celil Haskologlu

Dr. Haskologlu, Ismail Celil Haskologlu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2025 in Molecules
Verified
Journal Article
Open access
PDF file
KBKemal Husnu Can Baser
Kemal Husnu Can Baser
HHHaskologlu, Ismail Celil Haskologlu
Haskologlu, Ismail Celil Haskologlu
EEEMINE ERDAG
EMINE ERDAG
Circadian rhythms are molecular oscillations governed by transcriptional–translational feedback loops (TTFLs) operating in nearly all cell types and are fundamental to physiological homeostasis. Key circadian regulators, such as circadian locomotor output cycles kaput (CLOCK), brain and muscle ARNT-like 1 (BMAL1), period (PER), and cryptochrome (CRY) gene families, regulate intracellular metabolism, oxidative balance, mitochondrial function, and synaptic plasticity. Circadian disruption is known as a central contributor to the molecular pathophysiology of neurodegenerative disorders. Disease-specific disruptions in clock gene expression and melatoninergic signaling are known as potential early-stage molecular biomarkers. Melatonin, a neurohormone secreted by the pineal gland, modulates clock gene expression, mitochondrial stability, and inflammatory responses. It also regulates epigenetic and metabolic processes through nuclear receptors and metabolic regulators involved in circadian and cellular stress pathways, thereby exerting neuroprotective effects and maintaining neuronal integrity. This review provides recent findings from the past five years, highlighting how circadian dysregulation mediates key molecular and cellular disturbances and the translational potential of circadian-based therapies in neurodegenerative diseases.

Verified
Journal Article
Open access
PDF file
EEEMINE ERDAG
EMINE ERDAG
HHHaskologlu, Ismail Celil Haskologlu
Haskologlu, Ismail Celil Haskologlu
Background/Objectives: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, synaptic dysfunction, and neuronal loss. Although amyloid-β plaques and neurofibrillary tangles have been the historical hallmarks of AD pathology, growing evidence highlights microglial-mediated neuroinflammation as a central driver of disease onset and progression. This review aims to provide an updated overview of the dual roles of microglia in AD, from their protective functions to their contribution to chronic inflammation and neurodegeneration. Methods: This review synthesizes findings from recent experimental and clinical studies to examine the molecular mechanisms underlying microglial activation and dysfunction in AD. Key areas of focus include microglial signaling pathways, gut–brain axis interactions, and immunometabolic regulation. The review also evaluates emerging immunomodulatory therapeutic strategies designed to restore microglial homeostasis. Results: Recent studies reveal that microglia undergo a dynamic transition from a homeostatic to a reactive state in AD, contributing to sustained neuroinflammation and impaired clearance of pathological aggregates. Molecular mechanisms such as TREM2 signaling, NLRP3 inflammasome activation, and metabolic reprogramming play critical roles in this process. Additionally, gut microbiota alterations and systemic inflammation have been shown to influence microglial function, further exacerbating disease pathology. Conclusions: Targeting microglial dysfunction through immunomodulatory strategies holds promise as a disease-modifying approach in AD. Therapeutic avenues under investigation include natural compounds, synthetic modulators, immunotherapies, and microbiota-based interventions. A deeper mechanistic understanding of microglial regulation may open new translational pathways for the development of effective treatments for AD.

28 June 2025 in Records of Natural Products
Verified
Journal Article
Closed access
KBKemal Husnu Can Baser
Kemal Husnu Can Baser
HHHaskologlu, Ismail Celil Haskologlu
Haskologlu, Ismail Celil Haskologlu
EEEMINE ERDAG
EMINE ERDAG
Carvacrol, a monoterpenic phenol found abundantly in essential oils of Origanum, Thymus, Satureja, Thymbra and Lippia genera, is recognized for its extensive range of biological and pharmacological activities. This bioactive compound, primarily responsible for the health-promoting properties of oregano essential oil, exhibits diverse functionalities including antimicrobial, antitumor, antimutagenic, analgesic, anti-inflammatory, antioxidant, and neuroprotective effects. Its therapeutic applications extend to managing gastrointestinal ailments, reducing oxidative stress, and serving as an insecticidal agent. Furthermore, carvacrol has demonstrated potential as a feed additive and in honeybee breeding. Advances in encapsulation and nanotechnology have enhanced its stability and bioavailability, broadening its utility across food, pharmaceutical, and agricultural industries. This review synthesizes the evidence for carvacrol's biological activities and explores its possible in vivo mechanisms of action, emphasizing its promise as a natural therapeutic agent.

7 April 2022 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
HHHaskologlu, Ismail Celil Haskologlu
Haskologlu, Ismail Celil Haskologlu
EEEMINE ERDAG
EMINE ERDAG
Serkan SayınerSerkan Sayıner
Serkan Sayıner
NANurettin Abacioglu
Nurettin Abacioglu
ASAhmet Ozer Sehirli
Ahmet Ozer Sehirli

2 October 2023 in Chronobiology International
Verified
Journal Article
Closed access
EEEMINE ERDAG
EMINE ERDAG
HHHaskologlu, Ismail Celil Haskologlu
Haskologlu, Ismail Celil Haskologlu
MMMerve Mercan
Merve Mercan
NANurettin Abacioglu
Nurettin Abacioglu
ASAhmet Ozer Sehirli
Ahmet Ozer Sehirli
Chronobiology, which studies biological rhythms and their impacts on health, presents a potential avenue for treating amyotrophic lateral sclerosis. Clock gene-related therapies, focusing on genes responsible for regulating biological rhythms, may hold promise in the treatment. Among these clock genes, nuclear receptor subfamily 1 Group D member 1 (NR1D1) plays a vital role in neurodegenerative diseases. In this particular study, it was aimed to investigate the potential of FDA-approved drugs commonly used in amyotrophic lateral sclerosis treatment and melatonin, a hormone known for its role in regulating sleep-wake cycles, as ligands for clock gene-related therapy. The ligands were subjected to molecular docking and molecular dynamics simulation methods against the NR1D1 clock gene. These results suggested that combining melatonin with FDA-approved medications commonly used in the treatment might yield positive outcomes. This study provides preliminary data and lays the groundwork for future investigations involving in vitro (laboratory-based) and in vivo (animal or human-based) research on chronotherapy. In summary, this research highlights the potential of clock gene-related therapy utilizing melatonin in conjunction with FDA-approved drugs for amyotrophic lateral sclerosis treatment, offering insights into novel treatment strategies. The findings underscore the need for further studies to explore the effectiveness of this hypothetical approach in experimental and clinical settings.

1 December 2023 in Current Alzheimer Research
Verified
Journal Article
Closed access
PDF file
HHHaskologlu, Ismail Celil Haskologlu
Haskologlu, Ismail Celil Haskologlu
EEEMINE ERDAG
EMINE ERDAG
ASAhmet Ozer Sehirli
Ahmet Ozer Sehirli
OUOrhan Uludag
Orhan Uludag
NANurettin Abacioglu
Nurettin Abacioglu
Background: Alzheimer's Disease (AD) represents a neurodegenerative disorder characterized by cognitive and behavioral impairments significantly hindering social and occupational functioning. Melatonin, a hormone pivotal in regulating the body's intrinsic circadian rhythm, also acts as a catalyst in the breakdown of beta-amyloid deposits, offering a promising therapeutic approach for AD. The upregulation of Brain and Muscle ARNT-Like 1 (Bmal1) gene expression, stimulated by melatonin, emerges as a potential contributor to AD intervention. Current pharmacological interventions, such as FDA-approved cholinesterase inhibitors and the recently authorized monoclonal antibody, Lecanemab, are utilized in AD management. However, the connection between these medications and Bmal1 remains insufficiently explored. Objective: This study aims to investigate the molecular effects of FDA-endorsed drugs on the CLOCK: Bmal1 dimer. Furthermore, considering the interactions between melatonin and Bmal1, this research explores the potential synergistic efficacy of combining these pharmaceutical agents with melatonin for AD treatment. Methods: Using molecular docking and MM/PBSA methodologies, this research determines the binding affinities of drugs within the Bmal1 binding site, constructing interaction profiles. Results: The findings reveal that, among FDA-approved drugs, galanthamine and donepezil demonstrate notably similar binding energy values to melatonin, interacting within the Bmal1 binding site through analogous amino acid residues and functional groups. Conclusion: A novel therapeutic approach emerges, suggesting the combination of melatonin with Lecanemab as a monoclonal antibody therapy. Importantly, prior research has not explored the effects of FDA-approved drugs on Bmal1 expression or their potential for synergistic effects.